Observational studyAntimicrobial agents and chemotherapy2025
Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.
Eva Benavent, Jaime Lora-Tamayo, Marta Ulldemolins, Paula Pons-Oltra, Matthieu Gregoire, Mikel Mancheño-Losa, Pilar Hernández-Jiménez, M Ángeles Meléndez-Carmona, Victor Casals, Jason A Roberts and 2 more
Abstract readObservational Study
In one paragraphObservational study in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Eva Benavent *Infectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-9891-1766 Jaime Lora-Tamayo *Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Imas12, Madrid, Spain.
Marta UlldemolinsInfectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Paula Pons-OltraInfectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Matthieu GregoireUniversity of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.ORCID 0000-0003-1232-5761 Mikel Mancheño-LosaDepartment of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Imas12, Madrid, Spain.
Pilar Hernández-JiménezDepartment of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Imas12, Madrid, Spain.ORCID 0000-0003-4622-6278 M Ángeles Meléndez-CarmonaDepartment of Microbiology, Hospital Universitario 12 de Octubre, Instituto de Investigación Biomédica "imas12" Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0001-9582-3162 Victor CasalsOrthopedic Surgery Department, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Universitat de Barcelona, Barcelona, Spain.
Jason A RobertsUniversity of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Raul Rigo-BonninDepartment of Clinical Laboratory, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Oscar MurilloInfectious Diseases Department, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-5776-8422 Funding
Angelini Pharma 0000Fundación Alfonso Martín Escudero (Alfonso Martin Escudero Foundation) 0000Instituto de Salud Carlos III CM23/00259Instituto de Salud Carlos III JR23/00074Medical Research Council APP2007007Medical Research Council APP2009736
6 · The paper itselfAbstract
The efficacy, safety, and population pharmacokinetics of a single 1,500 mg dose of dalbavancin as a sequencing treatment for Gram-positive chronic prosthetic joint infections (CPJIs) have not been described. We present an observational, retrospective study conducted in two Spanish hospitals including patients with CPJI caused by Gram-positive bacteria susceptible to dalbavancin managed with two-stage exchange, antibiotic-loaded spacers, and a single 1,500 mg dose of dalbavancin. Follow-up visits included measurement of dalbavancin plasma concentrations. Negative intraoperative cultures at second-stage surgery defined microbiological cure. Population pharmacokinetics and Monte Carlo dosing simulations were used to evaluate whether this dose provided a therapeutic antibiotic exposure defined as the ratio between the area under the unbound concentration curve and the bacteria minimum inhibitory concentration (ƒAUC
Indexed as
Anti-Bacterial AgentsGram-Positive Bacterial InfectionsProsthesis-Related InfectionsTeicoplaninAgedAged, 80 and overFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMonte Carlo MethodRetrospective StudiesVancomycinAnti-Bacterial AgentsdalbavancinTeicoplaninVancomycinchronic prosthetic joint infectiondalbavancinlong-acting antibioticpharmacokinetic analysistwo-stage prosthetic exchange
Identifiers
PMID41105523
PMCPMC12691635
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390